ImmuCell Corporation (ICCC) Q4 FY25 Earnings Call

Capacity and margin initiatives support growth, but backorder comparisons and international volatility remain near-term constraints.

Q4 FY25 results, source: company transcript and SEC filings
QuarterQ4 FY25
Call date2026-03-06
Length23 minutes
EPS$-0.31
Revenue$7.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q2 FY25

All ICCC earnings ยท Back to ICCC overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.